Drug Profile
Uteroglobin
Alternative Names: Blastokinin; CC10; CC16; CCSP; CG 100; CG 367; CG201; CG459; Clara cell 10 kDa protein; Claragen; PCB-binding protein; Recombinant human CC10 protein; Recombinant human Clara cell 10 kDa protein; Recombinant human secretoglobin 1A1; rhCC10; SCGB1A1; Urine protein-1Latest Information Update: 10 Mar 2023
Price :
$50
*
At a glance
- Originator Unknown
- Developer Brigham and Womens Hospital; Therabron Therapeutics; Tufts-New England Medical Center
- Class Anti-inflammatories; Recombinant proteins; Respiratory stimulants
- Mechanism of Action Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bronchopulmonary dysplasia
- Phase I/II Sinusitis
- No development reported Bronchiolitis obliterans
- Discontinued Acute lung injury; Asthma; Burns; Chronic obstructive pulmonary disease; Influenza virus infections; Pneumonia; Respiratory distress syndrome
Most Recent Events
- 10 Mar 2023 Discontinued - Preclinical for Acute lung injury in USA (Parenteral)
- 10 Mar 2023 Discontinued - Preclinical for Asthma in USA (Inhalation)
- 10 Mar 2023 Discontinued - Preclinical for Burns in USA (Parenteral)